Key Highlights
- BioMarin and Ascendis Pharma finalized a worldwide settlement that ends all intellectual property litigation regarding Ascendis’s therapy Yuviwel.
- BioMarin will receive 20% royalties on Yuviwel’s U.S. net revenue and 18% on revenue from the European Union, Brazil, and South Korea.
- These royalty obligations begin retroactively from Yuviwel’s initial market launch and extend through May 2030.
- The licensing agreement encompasses every existing and future indication for Yuviwel, covering achondroplasia and hypochondroplasia treatments.
- As part of the agreement, BioMarin will withdraw its Section 337 complaint with the ITC and terminate associated legal proceedings worldwide.
On August 30, 2026, BioMarin Pharmaceutical (BMRN) finalized a comprehensive patent agreement with Ascendis Pharma, bringing closure to an intellectual property conflict concerning CNP technology embedded in Ascendis’s therapeutic product Yuviwel. At the time of this announcement, BMRN stock declined by 0.96%.
BioMarin Pharmaceutical Inc., BMRN
Both pharmaceutical companies had been engaged in contentious legal proceedings spanning numerous international venues, which included actions filed with the U.S. International Trade Commission. This comprehensive settlement consolidates the resolution of all outstanding matters into a single unified agreement.
According to the settlement terms, Ascendis will compensate BioMarin with royalties equaling 20% of Yuviwel’s net revenue from U.S. markets, with the obligation backdated to the product’s initial commercial launch date. For markets in the European Union, Brazil, and South Korea, Ascendis will remit 18% of net sales. These royalty obligations remain in effect until May 2030.
The licensing arrangement encompasses Yuviwel for every current and prospective medical application, spanning achondroplasia, hypochondroplasia, and any combination treatment protocols. This expansive coverage ensures BioMarin’s intellectual property protections extend far beyond the drug’s primary therapeutic indication.
Concessions and Gains in the Agreement
As consideration, BioMarin has committed to withdrawing its Section 337 complaint filed with the ITC. Outstanding litigation in Brazil, Denmark, Germany, South Korea, and California’s Northern District will similarly be dismissed.
Additionally, Ascendis has agreed to refrain from contesting BioMarin’s patent validity and has accepted reciprocal regulatory non-interference provisions. These represent substantial concessions on Ascendis’s part.
This settlement effectively vindicates BioMarin’s CNP technology platform, which encompasses its proprietary medication VOXZOGO (vosoritide) prescribed for pediatric patients diagnosed with achondroplasia. Following years of scientific development and research investment, the royalty arrangement represents a tangible financial return on BioMarin’s innovation efforts.
BioMarin’s Standing in Rare Disease Therapeutics
BioMarin’s Chief Executive Officer Alexander Hardy characterized this resolution as evidence that sustained investment in rare disease research and development yields meaningful rewards. The organization currently markets nine commercial products and has pioneered six first-in-disease therapeutic solutions.
The latest analyst assessment for BMRN maintains a Buy recommendation with an $88.00 price objective. The company’s market capitalization currently stands at approximately $12.52 billion.
From a technical analysis perspective, BioMarin’s sentiment registers as a Buy, with share prices trading above key moving average indicators and displaying positive MACD momentum. However, financial analysts have noted recent deterioration in profitability metrics and return on equity figures, coupled with an elevated price-to-earnings valuation.
During its latest quarterly earnings presentation, the company increased its 2026 revenue projections, providing favorable momentum as the company progresses through the remainder of the fiscal year.
This settlement establishes an additional royalty revenue channel linked to Yuviwel’s commercial performance across four significant geographic markets, which will contribute to BioMarin’s financial results continuously through May 2030.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
